Drug Shortage Report for MILRINONE LACTATE INJECTION, USP
Report ID | 164279 |
Drug Identification Number | 02244622 |
Brand name | MILRINONE LACTATE INJECTION, USP |
Common or Proper name | MILRINONE LACTATE INJECTION, USP |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | MILRINONE |
Strength(s) | 1MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 20mL |
ATC code | C01CE |
ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-07-04 |
Estimated end date | 2022-07-31 |
Actual end date | 2022-07-31 |
Shortage status | Resolved |
Updated date | 2022-08-03 |
Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, our Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL will be placed on allocation effective July 4, 2022. Contract customers will be allocated 100% of historical monthly demand. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2022-08-03 | French | Compare |
v3 | 2022-08-03 | English | Compare |
v2 | 2022-07-07 | French | Compare |
v1 | 2022-07-07 | English | Compare |
Showing 1 to 4 of 4